CLL BALL Score for Relapsed/Refractory CLL

The global unit selector only affects unanswered questions
1.B2M: Beta-2 microglobulin (B2M) ≥ 5mg/L?
2.Anemia: Male with Hgb < 120 g/L or Female with Hgb < 110 g/L?
3.LDH: LDH > upper limit of normal?
4.Last therapy: Time from initiation of last therapy < 24 months?
Created by

1. B2M: Beta-2 microglobulin (B2M) ≥ 5mg/L?

Created by
0/4 completed

About this Calculator

The Relapsed CLL BALL Score risk model was derived in a population of previously treated CLL patients who received protocol-based therapy in ibrutinib phase 3 trials, and was externally validated in three independent cohorts including a pooled dataset from idelalisib phase 3 trials, a venetoclax phase 3 trial, and the Mayo Clinic CLL Database.

The Relapsed CLL BALL Score consists of four factors, each assigned 1 point:

  • B2M: B2M >5mg/L
  • Anemia: Hemoglobin < 110 g/L
  • LDH: LDH > upper limit of normal
  • Last therapy: Time from initiation of last therapy < 24 months

The Relapsed CLL BALL Score identifies three prognostic groups (low risk, score 0-1; intermediate risk, score 2-3; high risk, score 4) with significantly different overall survival. Application of this risk model to patients with relapsed/refractory CLL reliably identifies patients at increased risk of death, and is validated for patients treated with all currently approved targeted therapies: ibrutinib, idelalisib, and venetoclax.

By applying the Relapsed CLL BALL Score to individual patients, treating physicians can identify patients at increased risk of death despite targeted therapies. We propose that high and intermediate risk patients should be evaluated for consideration in clinical trials, as their expected survival with modern targeted therapies remains suboptimal.

Investigators can address this unmet need by designing prospective trials targeting these higher risk patients.

Legal Notices and Disclaimer

© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.